This publication reports on newly diagnosed cancers registered in England in addition to cancer deaths registered in England during 2020. It includes this summary report showing key findings, spreadsheet tables with more detailed estimates, and a methodology document.

This statistic shows the number of deaths from cervical cancer in England from 2014 to 2021. In 2021, the number of deaths from cervical cancer reached 702, an increase from 681 deaths in 2020.

In 2020, approximately ** men and ** women per 100,000 population died from lung cancer in England and Wales. During the provided time interval, there has been a noticeable decrease in the mortality of lung cancer among men, while the rate among women has remained at similar levels since the year 2000.

Age-standardised rate of mortality from oral cancer (ICD-10 codes C00-C14) in persons of all ages and sexes per 100,000 population.RationaleOver the last decade in the UK (between 2003-2005 and 2012-2014), oral cancer mortality rates have increased by 20% for males and 19% for females1Five year survival rates are 56%. Most oral cancers are triggered by tobacco and alcohol, which together account for 75% of cases2. Cigarette smoking is associated with an increased risk of the more common forms of oral cancer. The risk among cigarette smokers is estimated to be 10 times that for non-smokers. More intense use of tobacco increases the risk, while ceasing to smoke for 10 years or more reduces it to almost the same as that of non-smokers3. Oral cancer mortality rates can be used in conjunction with registration data to inform service planning as well as comparing survival rates across areas of England to assess the impact of public health prevention policies such as smoking cessation.References:(1) Cancer Research Campaign. Cancer Statistics: Oral – UK. London: CRC, 2000.(2) Blot WJ, McLaughlin JK, Winn DM et al. Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res 1988; 48: 3282-7. (3) La Vecchia C, Tavani A, Franceschi S et al. Epidemiology and prevention of oral cancer. Oral Oncology 1997; 33: 302-12.Definition of numeratorAll cancer mortality for lip, oral cavity and pharynx (ICD-10 C00-C14) in the respective calendar years aggregated into quinary age bands (0-4, 5-9,…, 85-89, 90+). This does not include secondary cancers or recurrences. Data are reported according to the calendar year in which the cancer was diagnosed.Counts of deaths for years up to and including 2019 have been adjusted where needed to take account of the MUSE ICD-10 coding change introduced in 2020. Detailed guidance on the MUSE implementation is available at: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/articles/causeofdeathcodinginmortalitystatisticssoftwarechanges/january2020Counts of deaths for years up to and including 2013 have been double adjusted by applying comparability ratios from both the IRIS coding change and the MUSE coding change where needed to take account of both the MUSE ICD-10 coding change and the IRIS ICD-10 coding change introduced in 2014. The detailed guidance on the IRIS implementation is available at: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/impactoftheimplementationofirissoftwareforicd10causeofdeathcodingonmortalitystatisticsenglandandwales/2014-08-08Counts of deaths for years up to and including 2010 have been triple adjusted by applying comparability ratios from the 2011 coding change, the IRIS coding change and the MUSE coding change where needed to take account of the MUSE ICD-10 coding change, the IRIS ICD-10 coding change and the ICD-10 coding change introduced in 2011. The detailed guidance on the 2011 implementation is available at https://webarchive.nationalarchives.gov.uk/ukgwa/20160108084125/http://www.ons.gov.uk/ons/guide-method/classifications/international-standard-classifications/icd-10-for-mortality/comparability-ratios/index.htmlDefinition of denominatorPopulation-years (aggregated populations for the three years) for people of all ages, aggregated into quinary age bands (0-4, 5-9, …, 85-89, 90+)

Cancer diagnoses and age-standardised incidence rates for all types of cancer by age and sex including breast, prostate, lung and colorectal cancer.

Directly age and sex standardised mortality rate from Cancer for people aged under 75 in the respective calendar year per 100,000 registered patients March 2020: In addition to the changes in March 2019, the indicator production process has been fully automated. As a result there are two changes to this publication: 1) Data in this file are published from 2016 only; all data is based on the most recent methodology and comparable across years. For the historic time series of this indicator please refer to the zip files in the March 2019 publication: https://digital.nhs.uk/data-and-information/publications/clinical-indicators/ccg-outcomes-indicator-set/archive/ccg-outcomes-indicator-set---march-2019 2) Data are run against the CCG configuration at the time of processing; the 2016 and 2017 data points have been restated based on the new automated process. As of the March 2019 release the processing of the Primary Care Mortality Database (PCMD) and the standard population used to calculate the indicator for new data periods changed; this file now contains only those data periods processed under the new method. For the historic time series of this indicator please refer to the zip files in the March 2019 publication referenced above. Legacy unique identifier: P01808

The Office for Health Improvement and Disparities (OHID) has updated the mortality profile.

The profile brings together a selection of mortality indicators, including from other OHID data tools such as the https://fingertips.phe.org.uk/profile/public-health-outcomes-framework/data" class="govuk-link">Public Health Outcomes Framework, making it easier to assess outcomes across a range of causes of death.

For the March 2023 update, 12 new indicators have been added to the profile:

• mortality rate for deaths due to COVID-19, all ages
• under 75 mortality rate for deaths due to COVID-19
• mortality rate from all cardiovascular diseases, all ages
• mortality rate from heart disease, all ages
• mortality rate from stroke, all ages
• mortality rate from cancer, all ages
• mortality rate from breast cancer, all ages
• mortality rate from colorectal cancer, all ages
• mortality rate from liver disease, all ages
• mortality rate from respiratory disease, all ages
• under 75 mortality rate from lung cancer
• mortality rate from dementia and Alzheimer’s disease, all ages

If you would like to send us feedback on the tool please contact pha-ohid@dhsc.gov.uk.

This statistic shows the rate of registrations of newly diagnosed cases of prostate cancer per 100,000 population in England in 2020, by region. With a rate of 160.2 newly diagnosed males with prostate cancer per 100,000 population in 2020, the region most affected by prostate cancer was South East.

One-year and five-year net survival for adults (15-99) in England diagnosed with one of 29 common cancers, by age and sex.

Immuno Oncology Diagnosis Market Outlook

The global immuno oncology diagnosis market size was valued at $2.5 billion in 2023 and is projected to reach $7.9 billion by 2032, growing at a compound annual growth rate (CAGR) of 13.7% during the forecast period. This marketÂ’s growth is driven primarily by the rising incidence of cancer and advancements in diagnostic technologies that enable early and precise detection of oncological conditions.

One of the primary growth factors for the immuno oncology diagnosis market is the increasing prevalence of cancer globally. According to the World Health Organization (WHO), cancer is one of the leading causes of death worldwide, with approximately 19.3 million new cases and 10 million cancer-related deaths in 2020. The rising cancer incidence necessitates advanced diagnostic solutions to ensure early detection and effective treatment, thereby driving the demand for immuno oncology diagnostics. Additionally, the growing awareness about the importance of early cancer diagnosis among the general population and healthcare providers further fuels market growth.

Another significant growth factor is the advancements in diagnostic technologies. Innovations such as next-generation sequencing (NGS), polymerase chain reaction (PCR), immunohistochemistry (IHC), and flow cytometry have revolutionized the field of oncology diagnostics. These technologies offer enhanced accuracy, specificity, and sensitivity in detecting cancer biomarkers, thereby improving diagnostic outcomes. The integration of artificial intelligence (AI) and machine learning in diagnostic tools also holds immense potential for improving diagnostic efficiency and accuracy, further propelling market growth.

The increasing investment in cancer research and development by governments, healthcare organizations, and pharmaceutical companies is also a key driver for the market. Significant funding and grants are being allocated to cancer research initiatives to develop innovative diagnostic and treatment solutions. The collaboration between academic and research institutes, diagnostic laboratories, and biotechnology companies is fostering the development of advanced diagnostic assays, kits, and instruments, thereby contributing to market growth.

Immuno-Oncology is a rapidly evolving field that plays a crucial role in the development of innovative diagnostic and therapeutic solutions for cancer. This area focuses on harnessing the body's immune system to identify and combat cancer cells, offering a promising approach to cancer treatment. The integration of immuno-oncology in diagnostics has led to the development of advanced assays and biomarkers that enhance the precision of cancer detection and monitoring. By understanding the interactions between the immune system and cancer cells, researchers can develop targeted therapies that improve patient outcomes. The continuous advancements in immuno-oncology are expected to drive significant growth in the diagnostic market, providing new opportunities for early detection and personalized treatment strategies.

Regionally, North America holds the largest share of the immuno oncology diagnosis market, attributed to the presence of a well-established healthcare infrastructure, high adoption of advanced diagnostic technologies, and significant investment in cancer research. The Asia Pacific region is expected to witness the highest growth rate during the forecast period, driven by the increasing prevalence of cancer, improving healthcare infrastructure, and rising awareness about early cancer diagnosis. Europe also holds a significant market share, with countries like Germany, France, and the UK leading in cancer research and diagnostics.

Product Type Analysis

The product type segment of the immuno oncology diagnosis market includes assays, kits, reagents, instruments, and software. Assays are a crucial component in the diagnosis and monitoring of cancer as they provide detailed information about the presence and progression of the disease. These assays are designed to detect specific cancer biomarkers, thus aiding in accurate diagnosis and personalized treatment planning. The increasing demand for early and precise cancer diagnosis is driving the growth of the assays segment. Furthermore, the development of advanced assays with higher sensitivity and specificity is anticipated to boost the market growth.

Kits are another essential product type in the immuno oncology diagnosis

Legacy unique identifier: P01733

Directly age-sex standardised rate for patients with oral cavity cancer per 100,000 population.

Rationale

Tobacco is a known risk factor for oral cancers1. In England, 65% of hospital admissions (2014–15) for oral cancer and 64% of deaths (2014) due to oral cancer were attributed to smoking2. Oral cancer registration is therefore a direct measure of smoking-related harm. Given the high proportion of these registrations that are due to smoking, a reduction in the prevalence of smoking would reduce the incidence of oral cancer.

Towards a Smokefree Generation: A Tobacco Control Plan for England states that tobacco use remains one of our most significant public health challenges and that smoking is the single biggest cause of inequalities in death rates between the richest and poorest in our communities3. In January 2012 the Public Health Outcomes Framework was published, then updated in 2016. Smoking and smoking-related death play a key role in two of the four domains: Health Improvement and Preventing premature mortality4.

Definition of numerator

The number of diagnoses of patients with oral cavity cancer (ICD-10 code C00.3 to C00.5, C02 to C04 (excluding C02.4), C05.0, C06)

National Cancer Registry Dataset from the National Disease Registration Service

Definition of denominator

ONS mid-year population estimates aggregated into quinary age bands.

Office for National Statistics (ONS), Mid-year population estimates (based on 2011 census)

Methodology

Numerator data for each age sex band are divided by the respective denominator population data to give age sex specific admission rates for the area. These age sex specific rates are multiplied by the standard population for each age sex group respectively and aggregated across all the age sex groups to give the age sex adjusted count of admissions for the area. This age sex adjusted count of admissions is divided by the total standard population for the whole age sex range included in the indicator, and multiplied by 100,000 to give the age sex standardised admission rate for the area.

Caveats Age sex standardised rates based on numbers lower than 10 are not included

References

GBD 2013 Risk Factors Collaborators. Global, regional and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risk factors in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. The Lancet 2015; 386:10010 2287–2323. Statistics on smoking, England 2016, May 2016; http://content.digital.nhs.uk/catalogue/PUB20781 Towards a Smokefree Generation: A Tobacco Control Plan for England, July 2017 Public Health Outcomes Framework 2016 to 2019, August 2016 Huggett C (1995). Review of the Quality and Comparability of Data held by Regional Cancer Registries. Bristol: Bristol Cancer Epidemiology Unit incorporating the South West Cancer Registry. Seddon DJ, Williams EMI (1997). Data quality in population-based cancer registration. British Journal of Cancer 76: 667–674.

In 2022, Australia had the fourth-highest total number of skin cancer cases worldwide and the highest age-standardized rate, with roughly 37 cases of skin cancer per 100,000 population. The graph illustrates the rate of skin cancer in the countries with the highest skin cancer rates worldwide in 2022.

Snapshot img

Glioblastoma Multiforme Treatment Market Size 2024-2028

The glioblastoma multiforme treatment market size is forecast to increase by USD 1.36 billion at a CAGR of 8.2% between 2023 and 2028.

The glioblastoma multiforme (GBM) treatment market is experiencing significant growth due to the rising incidence of this aggressive brain cancer and increasing research and development activities In the healthcare sector. According to the American Brain Tumor Association's Cancer Observatory, GBM accounts for approximately 15% of all primary brain tumors and is the most common malignant brain tumor in adults. Current treatment options include surgery, targeted therapy, and chemotherapy. Surgery remains the primary treatment modality for GBM, with various options such as awake craniotomy and awake craniotomy with intraoperative monitoring. This includes various strategies such as checkpoint inhibitors, monoclonal antibodies, and gene therapy. However, these procedures come with adverse effects such as cognitive impairment and motor deficits. Targeted therapies, such as temozolomide, are used in conjunction with surgery and chemotherapy to improve patient outcomes. The pharmaceutical supply chain plays a crucial role in ensuring the timely availability of these treatments to patients. Despite advancements in treatment options, the high mortality rate associated with GBM necessitates continued research and development efforts to improve patient outcomes and quality of life.

What will be the Size of the Glioblastoma Multiforme Treatment Market During the Forecast Period?

Request Free Sample

Glioblastoma multiforme (GBM), a malignant tumor of the central nervous system (CNS), is a significant health concern worldwide. According to the Global Cancer Observatory, CNS cancers accounted for approximately 2.3% of all cancer diagnoses and 2.5% of cancer deaths in 2020. This article provides an overview of the current treatment landscape for GBM, focusing on surgical, radiation, chemotherapy, targeted therapy, immunotherapy, and emerging novel therapies. Surgery is the primary treatment modality for GBM, with the primary goal being to remove as much of the tumor as possible while minimizing damage to healthy brain tissue. Ambulatory surgical centers and hospitals offer various surgical procedures, including craniotomy and awake craniotomy. Following surgery, patients typically undergo radiation therapy to target any remaining cancer cells. External beam radiation therapy (EBRT) is the most common approach, delivering high-energy radiation to the tumor site. Chemotherapy is often used in combination with radiation therapy to enhance the therapeutic effect.
Moreover, temozolomide, a chemotherapeutic agent, is the most widely used drug for GBM treatment. Corticosteroids, such as dexamethasone, are also frequently administered to reduce swelling and improve symptoms. Targeted therapies, such as bevacizumab, are designed to specifically target the molecular mechanisms of GBM. These therapies inhibit the growth and spread of cancer cells by blocking the action of specific proteins. Moreover, combination Therapies: Combination therapies, which involve the use of multiple treatment modalities, are increasingly being explored to improve treatment outcomes for GBM. For example, the combination of temozolomide and radiation therapy has been shown to improve survival rates compared to monotherapy. Immunotherapy: Immunotherapy, which harnesses the power of the immune system to fight cancer, is an emerging treatment approach for GBM. Personalized Medicine: The heterogeneity of GBM necessitates personalized treatment approaches.
Thus, drug classes and treatment procedures are being tailored to individual patients based on their unique tumor characteristics, such as genetic mutations and protein expression profiles. The treatment market for GBM is continually evolving, with a focus on developing novel therapies and combination strategies to improve patient outcomes. The pharmaceutical supply chain plays a crucial role in ensuring the availability and accessibility of these treatments. As the understanding of GBM biology deepens, so too will the range and effectiveness of treatment options.

How is this Glioblastoma Multiforme Treatment Industry segmented and which is the largest segment?

The glioblastoma multiforme treatment industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

End-user

  Hospitals
  Clinics
  Ambulatory surgical centers


Geography

  North America

    Canada
    US


  Europe

    Germany
    UK


  Asia

    China


  Rest of World (ROW)

By End-user Insights

The hospitals segment is estimated to witness significant growth during the forecast period.

Snapshot img

Oncology Drugs Market Size 2025-2029

The oncology drugs market size is forecast to increase by USD 215.9 billion at a CAGR of 13.4% between 2024 and 2029.

The market is experiencing significant growth, driven by the increasing prevalence of cancer globally and the rising adoption of immunotherapy. According to the World Health Organization, there were approximately 19.3 million new cancer cases and nearly 10.0 million cancer deaths in 2020. This trend is expected to continue, fueling the demand for innovative and effective oncology drugs. This sector is witnessing the integration of advanced technologies like next-generation sequencing (NGS), chips, and microarrays in clinical testing and clinical trials. However, the high cost of cancer treatment drugs poses a significant challenge to market growth. Despite the potential benefits, the affordability of these therapies remains a major concern for patients and healthcare systems. Reagents and kits are indispensable in molecular diagnostic tests, facilitating the detection of genetic mutations, gene expression patterns, or protein markers.
This issue is further complicated by the complex reimbursement landscape and regulatory requirements. To capitalize on market opportunities and navigate these challenges effectively, companies must focus on developing cost-effective solutions while maintaining therapeutic efficacy. Additionally, collaborations and partnerships between industry players, academic institutions, and regulatory bodies can help drive innovation and improve patient access to life-saving treatments.

What will be the Size of the Oncology Drugs Market during the forecast period?

Request Free Sample

The market encompasses a diverse range of prescription medications designed to treat various types of cancer, including breast, lung, colon, prostate, liver, esophagus, cervical, kidney, and bladder cancers. These therapies incorporate advanced technologies such as targeted therapy and hormone therapy, which aim to selectively attack cancer cells while minimizing harm to healthy cells. The market's growth is driven by the increasing prevalence of cancer worldwide, advancements in drug discovery and development, and the expanding use of artificial intelligence in oncology research and personalized treatment plans.
Clinical trials continue to explore new drug classes and combinations, further expanding the therapeutic landscape. Reimbursement policies and access to oncology drugs through hospital pharmacies, retail pharmacies, and online platforms influence market dynamics. Overall, the market is a significant and evolving sector within the prescription drug industry.

How is this Oncology Drugs Industry segmented?

The oncology drugs industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Therapy

  Targeted therapy
  Immunotherapy and hormonal therapy
  Chemotherapy


Distribution Channel

  Offline
  Online


Form Factor

  Solid
  Liquid
  Injectable


Indication

  Lung cancer
  Colorectal cancer
  Stomach cancer
  Others


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    Italy
    The Netherlands
    UK


  Asia
  Rest of World (ROW)

By Therapy Insights

The targeted therapy segment is estimated to witness significant growth during the forecast period. Targeted therapy represents a subcategory of oncology drugs, specifically a type of precision cancer treatment that utilizes biological drugs and monoclonal antibodies to inhibit cancer cell growth. Unlike traditional chemotherapy, which indiscriminately targets fast-growing cells, targeted therapy focuses on specific features in cancer cells, minimizing damage to healthy cells. This approach is particularly effective in managing advanced-stage cancers, such as lung, stomach, colorectal, breast, prostate, liver, esophagus, cervical, kidney, and bladder cancers. Targeted therapies include Fulvestrant Injection for hormone therapy, kinase inhibitors, angiogenesis inhibitors, and immunotherapies. Clinical trials and drug pipeline research continue to expand the scope of targeted therapies, with new molecular entities and combination therapies under development.

Reimbursement policies and access to oncology drugs through hospital pharmacies, retail pharmacies, and online pharmacies remain essential considerations for patients and healthcare providers.

Get a glance at the market report of share of various segments Request Free Sample

The Targeted therapy segment was valued at USD 82.20 billion in 2019 and showed a gradual increase during the forecast period.

Regional Analysis

North America is estimated to contribute 45% to the growth of the global market during the forecast period. Tech

Snapshot img

Bispecific Antibodies For Cancer Market Size 2025-2029

The bispecific antibodies for cancer market size is forecast to increase by USD 338 million at a CAGR of 6.9% between 2024 and 2029.

The market is witnessing significant growth, driven primarily by the increasing prevalence of cancer worldwide. According to the World Health Organization, there were approximately 19.3 million new cancer cases and nearly 10.0 million cancer deaths in 2020. This increasing burden of cancer is fueling the demand for innovative therapeutic solutions, making the market an attractive proposition for investors and pharmaceutical companies. Another key driver for the market is the emergence of advanced bispecific antibody generation platforms. These platforms enable the development of bispecific antibodies with enhanced specificity and efficacy, offering significant advantages over traditional monoclonal antibodies.
However, the high cost of these drugs poses a significant challenge to market growth. Despite their potential benefits, the high production costs and expensive pricing structures limit their accessibility to a large patient population. Therefore, companies in the market must focus on developing cost-effective manufacturing processes and pricing strategies to expand their reach and capture a larger market share.

What will be the Size of the Bispecific Antibodies For Cancer Market during the forecast period?

Request Free Sample

The bispecific antibodies market for cancer treatment continues to evolve, driven by the complexities of advanced cancer and the need for innovative therapeutic approaches. These antibodies, which bind to two distinct antigens, offer potential benefits in addressing tumor heterogeneity and overcoming drug resistance. Bispecific antibodies are currently being explored in various sectors, including solid tumors and hematologic malignancies. Response rates have shown promise in clinical trials, particularly in relapsed cancer patients. Research collaborations between academic institutions and industry partners are accelerating the pace of drug development. The tumor microenvironment plays a crucial role in cancer progression, and bispecific antibodies are being engineered to target immune checkpoints such as PD-1 and CTLA-4, as well as CAR T-cell therapy targets.
Precision medicine and personalized treatment approaches are also gaining traction, with an emphasis on clinical endpoints like progression-free survival and overall survival. Industry partnerships and patient advocacy groups are collaborating to reduce treatment costs and improve disease awareness. The regulatory approval process for bispecific antibodies is ongoing, with a focus on ensuring safety and efficacy. Antibody drug conjugates and complement-dependent cytotoxicity are among the emerging strategies being explored to enhance the therapeutic potential of bispecific antibodies. In the evolving landscape of cancer therapy, bispecific antibodies represent a promising avenue for addressing the complexities of refractory cancer and improving patient quality of life.
The ongoing research and development efforts in this area underscore the dynamic nature of the market and the potential for continued innovation.

How is this Bispecific Antibodies For Cancer Industry segmented?

The bispecific antibodies for cancer industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Type

  CD19 or CD3
  CD30 or CD16A


Distribution Channel

  Hospitals
  Retail pharmacies
  Online


Action Mechanism

  Dual antigen targeting
  Dual-blocking antibodies
  T-cell engagers


Therapeutic Area

  Oncology
  Autoimmune diseases
  Infectious diseases
  Neurological disorders


Geography

  North America

    US
    Canada


  Europe

    Germany
    Hungary
    Ireland
    UK


  APAC

    China
    India
    Japan


  South America

    Brazil


  Rest of World (ROW)

By Type Insights

The CD19 or CD3 segment is estimated to witness significant growth during the forecast period.

The market is experiencing significant growth due to the increasing prevalence of various types of cancer, particularly acute lymphoblastic leukemia (ALL), which affects approximately 6,450 new patients and results in around 1,300 deaths annually in the US. This demand for novel cancer treatments is driven by the need to address the complexities of tumor heterogeneity and drug resistance in relapsed cancer patients. Academic institutions and industry partnerships are collaborating to advance drug development through research collaborations and clinical trials. Bispecific antibodies, such as Blinatumomab, a CD19 or CD3 bispecific antibody designed in the BiTEs format, have emerged as promising therapeutic

The UK mammography market, a segment of the broader global market valued at $83.72 billion in 2025 and exhibiting a robust Compound Annual Growth Rate (CAGR) of 8.74%, is poised for significant expansion over the forecast period (2025-2033). Driven by increasing breast cancer awareness, improved diagnostic imaging technologies (including digital mammography and tomosynthesis), and expanding healthcare infrastructure, the UK market is experiencing heightened demand for these essential screening and diagnostic services. The prevalence of breast cancer, a leading cause of cancer-related deaths in women, necessitates widespread screening programs, fueling market growth. Furthermore, technological advancements, such as AI-powered image analysis for improved accuracy and efficiency, are contributing to market expansion. While regulatory hurdles and high equipment costs might present challenges, the long-term outlook for the UK mammography market remains positive, driven by government initiatives promoting preventative healthcare and early detection of breast cancer. The market segmentation within the UK reflects global trends, with digital mammography systems capturing a significant share due to their superior image quality and efficiency. Hospitals and large diagnostic centers constitute the major end-users, although the role of specialty clinics is growing, facilitated by technological advancements making advanced imaging more accessible. Key players in the UK market, mirroring the global landscape, include established medical technology companies like Siemens Healthineers, GE Healthcare, and Philips, alongside specialized manufacturers focusing on mammography technology. The competitive landscape is characterized by ongoing innovation, with companies investing in research and development to improve image quality, reduce radiation exposure, and integrate AI-based analysis tools. The UK market's future growth will depend on continued investment in healthcare infrastructure, advancements in mammography technology, and effective public health initiatives promoting breast cancer awareness and early detection. We can expect further market consolidation and the emergence of innovative solutions. Recent developments include: In May 2021, the Amulet Innovality mammography system's Harmony version was introduced by Fujifilm United Kingdom (UK). The designs were created in the UK in association with the Fujifilm women's health team, and the package also comes with gantry decals and sophisticated room embellishment choices., In June 2020, Lunit revealed that Lunit INSIGHT MMG, their AI breast cancer treatment, has received CE certification and is commercially available throughout the European Economic Area, including the United Kingdom, 27 member countries of the European Union, and the European Free Trade Association.. Key drivers for this market are: Growing Burden of Breast Cancer, Technological Advancements in the Field of Breast Imaging; Investment from Various Organizations in Breast Cancer Screening Campaigns. Potential restraints include: Growing Burden of Breast Cancer, Technological Advancements in the Field of Breast Imaging; Investment from Various Organizations in Breast Cancer Screening Campaigns. Notable trends are: Hospital Segment is Expected to Hold a Significant Market Share Over the Forecast Period.

Total averted deaths per year across top 5 companies with greatest potential to reduce death from full compliance with the Australian government’s 2020 sodium reformulation targets.

The global Cancer Immunotherapy Market was valued at USD 128.74 Billion in 2023 and is projected to reach USD 238.38 Billion by 2030, registering a CAGR of 9.2% for the forecast period 2024-2030. The key driving factors for the Cancer Immunotherapy Market

The surging worldwide incidence of cancer, coupled with significant investments in the research and development of groundbreaking oncology therapies eventually drives the cancer immunotherapy market growth.

The global population continues to grow, and as people age, the risk of developing cancer increases. With more people living longer, there is a higher prevalence of cancer diagnoses. Modern lifestyles characterized by poor dietary habits, lack of physical activity, and increased exposure to environmental carcinogens have contributed to the rising incidence of cancer. Advances in medical imaging and diagnostic technologies have led to earlier and more accurate cancer detection, leading to an increase in reported cases. The use of tobacco and alcohol, known carcinogens, remains a significant contributor to cancer incidence, particularly in lung, liver, and oral cancers.

For instance, the Parker Institute for Cancer Immunotherapy has forged partnerships with researchers and industry experts to pioneer revolutionary immune-based cancer therapies. According to data from the Global Cancer Observatory, the United States recorded approximately 2,281,658 cancer diagnoses and 612,390 cancer-related fatalities in 2020. The prevalent malignancies impacting the U.S. populace encompass breast, prostate, lung, and colorectal cancers.
For instance, data from the Cancer Council reveals that Australia documented 150,000 new cancer diagnoses and 50,000 cancer-related fatalities in 2020. Consequently, the notable increase in the incidence of cancer cases is expected to propel market growth in the foreseeable future.
For instance, the Cancer Research Institute has provided funding for over 120 clinical trials and has allocated approximately USD 474 million towards research endeavors. Additionally, the Society for Immunotherapy of Cancer (SITC) is actively committed to enhancing patient outcomes by advancing the field of oncology immunotherapy. These organizations collaborate closely with scientists and researchers to explore innovative immune therapy treatment approaches.
For instance, In June 2022, a team of researchers at Stanford University secured a grant of USD 13 million from Cancer Grand Challenges, an initiative jointly supported by Cancer Research UK and the U.S. National Cancer Institute. This financial support has been granted to advance the development of cutting-edge immunotherapies, explore extrachromosomal DNA, and delve into the study of early-stage cancer

Expanding indications & personalized medicines significantly boost the cancer immunotherapy market growth.

Immunotherapies are being explored for a wide range of cancer types, including melanoma, lung cancer, bladder cancer, breast cancer, and more. As research uncovers new targets and mechanisms, the potential applications of immunotherapy continue to expand. Advances in understanding the genetic and molecular characteristics of tumors have led to the development of personalized immunotherapies. Tailoring treatments to an individual's unique tumor profile can improve response rates and reduce side effects. Thus, expanding indications & personalized medicines eventually boost the cancer immunotherapy market growth.

The Restraining Factor of Cancer Immunotherapy Market

Autoimmune reactions & skin reactions may restrain the cancer immunotherapy market growth.

Immunotherapies can trigger autoimmune reactions where the immune system mistakenly targets and damages normal cells or tissues, leading to conditions such as colitis, hepatitis, thyroiditis, and pneumonitis. Rashes, itching, and more severe skin conditions like dermatitis and bullous pemphigoid can occur as a result of immunotherapy. These several factors may hamper the cancer immunotherapy market growth.

Impact of the COVID-19 Pandemic on the Cancer Immunotherapy Market

Clinical trials are essential for testing the safety and efficacy of new cancer immunotherapies. The pandemic disrupted many clinical trials, leading to delays in drug development and regulatory approvals. These delays have affected the introduction of new treatments to the market. Shifts in Healthcare Resources: Hea...

Total averted deaths per year across top 5 companies with greatest potential to reduce death from full compliance with the Australian government’s 2020 sodium reformulation targets.